Trial Profile
A PROSPECTIVE, RANDOMIZED, OPEN LABEL BLINDED END POINT (PROBE), CROSS-OVER STUDY TO COMPARE THE EFFECTS OF TELMISARTAN AND LOSARTAN ON METABOLIC PROFILE OF RENAL TRANSPLANT PATIENTS.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Losartan (Primary) ; Telmisartan (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms COSTANT
- 22 Feb 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01224860).
- 02 Aug 2011 New trial record